3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
14
Polycystic Ovary Syndrome
9
Neoplasms
5
Endometrial Neoplasms
3
Prostatic Neoplasms
2
Peripheral Nervous System Diseases
2
Obesity
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Leiomyoma
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Glioblastoma
2
Diabetes Mellitus
2
Colorectal Neoplasms
2
Cognitive Dysfunction
2
Cardiotoxicity
2
Weight Gain
1
Vomiting
1
Venous Thromboembolism
1
Vascular Malformations
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Interventions
fludarabine phosphate
21
Cyclophosphamide
20
Peripheral Blood Stem Cell Transplantation
19
Busulfan
16
Tacrolimus
14
Whole-Body Irradiation
12
Methotrexate
12
Mycophenolic Acid
11
Cyclosporine
11
Antilymphocyte Serum
10
fludarabine
6
Filgrastim
6
peginterferon alfa-2a
5
ruxolitinib
4
Radiotherapy
4
Methylprednisolone
4
Melphalan
4
Flow Cytometry
4
Etoposide
4
Decitabine
4
Aspirin
4
Stem Cell Transplantation
3
Injections
3
Cytogenetic Analysis
3
Cytarabine
3
Biopsy
3
Azacitidine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
merphos
2
aldesleukin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Thrombocythemia, Essential
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled